
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has experienced a significant stock appreciation of nearly 90% over the last month, reflecting increased investor confidence bolstered by promising data from the PATHFINDER 2 ESMO study. The company is projected to tap into a large total addressable market (TAM) estimated at approximately $3.7 billion in the UK by 2026 and growing to about $4.0 billion by 2035, driven by its multi-cancer early detection blood test and strategic partnerships. Despite uncertainties regarding FDA approval and Medicare reimbursement, the positive study results and a substantial balance sheet enhancement of over $400 million contribute to a bullish outlook on GRAIL's future growth potential.
Bears say
GRAIL Inc has consistently recorded significant net losses since its inception and anticipates ongoing financial difficulties as it pursues regulatory approvals and expands its facilities. The company faces multiple risks, including potential delays in Congressional actions regarding reimbursement for its multi-cancer early detection (MCED) tests, headwinds in market adoption, and competitive pressures from established diagnostics companies with greater scale and resources. Additionally, increased selling, general, and administrative expenses related to growing Galleri volumes, alongside potential challenges in securing necessary financing for product commercialization, further exacerbate GRAIL's negative outlook.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares